Education
About Us
Working with TipRanks
Follow Us
Brian Adams Insider Profile
4 Followers
Brian Adams, GC & Secretary at Keryx Biopharma, holds 391.38K shares in Relay Therapeutics (Ticker: RLAY), holds 126.07K shares in Keryx Biopharma (Ticker: KERX). Most recently, Brian Adams Sold ― shares of Relay Therapeutics on Apr 30, 2025 for an estimated value of 44.04K.
Profitable Transactions
43 out of 53 Profitable Transactions
Average Return
+26.70%
Average return per transaction
Time Frame
Compare to
Insider Roles
CLO
Roles that Brian Adams holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Nov 01, 2022 - Nov 01, 2023
Return:+69.50%
The most profitable trade made by Brian Adams
Brian Adams's Trading History
Keryx Biopharma
Feb 16, 2018
―
Informative Sell
27.19K
$423.59K
Relay Therapeutics
Apr 30, 2025
CLO
Informative Sell
44.04K
$1.37M
List of latest transactions for each holding click on a transaction to see Brian Adams's performance on stock
You May Also Like
Brian Adams insider profile FAQ
What is the percentage of profitable transactions made by Brian Adams?
The percentage of profitable transactions made by Brian Adams is 81%.
What is the average return per transaction made by Brian Adams?
The average return per transaction made by Brian Adams is 26.70%.
What stocks does Brian Adams hold?
Brian Adams holds: KERX, RLAY stocks.
What was Brian Adams’s latest transaction?
Brian Adams latest transaction was an Informative Sell of $44.04K.
What was Brian Adams's most profitable transaction?
Brian Adams’s most profitable transaction was an Informative Sell of RLAY stock on November 1, 2022. The return on the trade was 69.50%.
What is Brian Adams's role in Keryx Biopharma?
Brian Adams's role in Keryx Biopharma is GC & Secretary.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.